[VIRTUAL] Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

[VIRTUAL] Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma – a Phase II Study

[VIRTUAL] Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Adding Steam to ASCT

[VIRTUAL] Phase I Study De-Intensifying Exposure of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies

[VIRTUAL] Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders

[VIRTUAL] Single Cell Cytokine Analysis of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 & IL-15

[VIRTUAL] Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses

[VIRTUAL] Clinical and Manufacturing Outcomes of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 & IL-15

[VIRTUAL] Phase II Study of Mega-Dose 90y-Ibritumomab Tiuxetan, Fludarabine and Low-Dose TBI Followed By Allogeneic Hematopoietic Transplantation for Relapsed or Refractory Aggressive Large B-Cell Lymphoma: Long-Term Outcomes

[VIRTUAL] Results of an Open Label Dose Escalation Trial of AB-205 (E-CEL® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT).

[VIRTUAL] Comparable Outcomes for Matched and Mismatched Unrelated Donor (URD) Transplantation with the Addition of Abatacept to Standard Graft Versus Host Disease Prophylaxis.

[VIRTUAL] Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

[VIRTUAL] Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

[VIRTUAL] A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211-At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS): Preliminary Results of Dose Escalation

[VIRTUAL] Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma